Patents Assigned to XAVIER UNIVERSITY OF LOUISIANA
-
Patent number: 11912660Abstract: The present disclosure relates to compounds that act as protein kinase inhibitors, especially RPS6K1 and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ and/or HER2+ breast cancer, prostate cancer, lung cancer, and metastatic cancer.Type: GrantFiled: April 16, 2021Date of Patent: February 27, 2024Assignee: Xavier University of LouisianaInventors: Jayalakshmi Sridhar, Melyssa Bratton, Rajesh Komati
-
Patent number: 11708381Abstract: The present disclosure relates to androgen receptor signaling inhibitors and the synthesis of the same. Further, the present disclosure teaches the utilization of the androgen receptor signaling inhibitors in a treatment for proliferative diseases, including cancer, particularly prostate cancer, and especially castration-resistant prostate cancer.Type: GrantFiled: November 22, 2017Date of Patent: July 25, 2023Assignee: XAVIER UNIVERSITY OF LOUISIANAInventors: Guangdi Wang, Jiawang Liu, Shilong Zheng, Shanchun Guo
-
Patent number: 11098053Abstract: Disclosed are daidzein analogs having the formula (I). Also disclosed are compositions, include a disclosed daidzein analogs, methods of preventing or treating bone disease or bone injury and/or stimulating bone growth, in a subject that include administering to the subject an effective amount of disclosed daidzein analog. Disclosed are isolated mesenchymal stem cell that has been altered by treatment a disclosed daidzein analog, daidzein, glycinol, glyceollin I, or glyceollin II, to increase the osteogenic potential of the mesenchymal stem cells.Type: GrantFiled: April 4, 2014Date of Patent: August 24, 2021Assignees: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, XAVIER UNIVERSITY OF LOUISIANA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTUREInventors: Amy Strong, Stephen Boue, Matthew Burow, Bruce Bunnell, Quan Jiang, Shilong Zheng, Guangdi Wang
-
Patent number: 11046715Abstract: The present disclosure relates to boronic derivatives of hydroxamate compounds, methods for making the same, methods for use as a monotherapy or in combination with one or more other therapeutic agents, for treatment of proliferative diseases such as cancer. The present disclosure also teaches the utilization of said boronic derivatives of hydroxamates as epigenetic therapy medications with enhanced bioavailability, lower-toxicity, and longer-lasting efficacy.Type: GrantFiled: November 27, 2017Date of Patent: June 29, 2021Assignee: Xavier University of LouisianaInventors: Guangdi Wang, Shilong Zheng, Jiawang Liu, Qiu Zhong, Shanchun Guo
-
Patent number: 9669004Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.Type: GrantFiled: January 15, 2015Date of Patent: June 6, 2017Assignees: The Administrators of the Tulane Educational Fund, United States Department of Agriculture, Xavier University of LouisianaInventors: Guangdi Wang, Matthew E. Burow, Stephen M. Boue, Thomas E. Wiese, Quan Jiang
-
Patent number: 9650369Abstract: Thiazole analog compounds and their pharmaceutically acceptable salts are disclosed, including pharmaceutical compositions comprising the thiazole analog compounds, either alone or in combination with at least one additional therapeutic agent, and/or with a pharmaceutically acceptable carrier. Methods of using the thiazole analog compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative diseases, such as cancer, are also disclosed.Type: GrantFiled: September 27, 2013Date of Patent: May 16, 2017Assignee: XAVIER UNIVERSITY OF LOUISIANAInventors: Guangdi Wang, Quan Jiang, Qiu Zhong, Qiang Zhang, Shilong Zheng
-
Patent number: 9636299Abstract: Compositions useful for treatment of retinal pathologies, including diabetic retinopathy, and methods of making and using said compositions, are provided.Type: GrantFiled: March 15, 2013Date of Patent: May 2, 2017Assignee: XAVIER UNIVERSITY OF LOUISIANAInventor: Partha S. Bhattacharjee
-
Patent number: 9353132Abstract: The present disclosure relates to boron-based 4-hydroxytamoxifen and endoxifen prodrugs and the synthesis of the same. Further, the present disclosure teaches the utilization of the boron-based 4-hydroxytamoxifen and endoxifen prodrugs in a treatment for breast cancer.Type: GrantFiled: March 5, 2013Date of Patent: May 31, 2016Assignee: XAVIER UNIVERSITY OF LOUISIANAInventors: Guangdi Wang, Shilong Zheng, Quan Jiang, Qiu Zhong, Qiang Zhang
-
Patent number: 8962679Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.Type: GrantFiled: July 8, 2011Date of Patent: February 24, 2015Assignees: The Administrators of the Tulane Educational Fund, Xavier University of LouisianaInventors: Guangdi Wang, Matthew E. Burow, Stephen M. Boue, Thomas E. Wiese, Quan Jiang
-
Publication number: 20150045296Abstract: Compositions useful for treatment of retinal pathologies, including diabetic retinopathy, and methods of making and using said compositions, are provided.Type: ApplicationFiled: March 15, 2013Publication date: February 12, 2015Applicant: XAVIER UNIVERSITY OF LOUISIANAInventor: Partha S. Bhattacharjee
-
Patent number: 8628701Abstract: A method of preparing micro-capsules. The active ingredient, preferably provided in the form of an acid salt dissolved in a basic aqueous solution, is emulsified into a polymer solution, preferably PLGA in a relatively volatile solvent such as dichloromethane, to create a water in oil emulsion. This emulsion is further emulsified into an aqueous solution having a pH of a between about 7.4 and 8.0 and most preferably between about 7.8 and 8.0 to create a water in oil in water solution. The polymer solvent is allowed to evaporate, causing the emulsified active ingredient and surrounding polymer matrix to precipitate, thereby forming the micro-capsules. The micro-capsules are separated from the suspension, washed and freeze dried. The method has a very high encapsulation efficiency, even at high loading rates. Additionally, the dissolution rate of the micro-particles produced by the method is very steady over a long period of time.Type: GrantFiled: October 31, 2006Date of Patent: January 14, 2014Assignee: Xavier University of LouisianaInventors: Tarun K. Mandal, Richard Graves
-
Patent number: 8563599Abstract: Two distinct methods are disclosed and claimed for synthesizing glyceollin I plus glyceollin II as a mixture and as their pure forms. Stereochemical isomers and various synthetic intermediates are also synthesized and claimed for their novel compositions of matter. All compounds and their mixtures are claimed for use in formulations that are useful to treat or prevent cancer, or that have utility as selective estrogen receptor modulators, such formulations including enhanced or medical foods, dietary supplements and ethical pharmaceutical agents.Type: GrantFiled: March 3, 2009Date of Patent: October 22, 2013Assignees: The United States of America, represented by the Secretary of Agriculture, Xavier University of Louisiana, University of ToledoInventors: Paul W. Erhardt, Rahul Khupse, Jefferey G. Sarver, Thomas E. Cleveland, Stephen M. Boue, Thomas E. Wiese, Matthew E. Burow, John A. McLachlan
-
Publication number: 20120308642Abstract: Compositions are disclosed of combinations of small interfering RNAs (siRNA) that can inhibit the replication of hepatitis C virus (HCV) in liver cells, along with methods of co-administering the siRNAs to subjects. Further, methods are disclosed for improving the delivery of nucleic acids to the liver.Type: ApplicationFiled: May 29, 2012Publication date: December 6, 2012Applicants: XAVIER UNIVERSITY OF LOUISIANA, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Srikanta DASH, Tarun K. MANDAL, Partha K. CHANDRA, Anup KUNDU, Sidhartha HAZARI
-
Publication number: 20120027844Abstract: Compounds and their syntheses are disclosed herein. Compositions and pharmaceutical compositions comprising a compound are also described, and include compositions also comprising liposomes. Methods for the treatment of cancer in animals comprising administering a compound or a composition comprising a compound are also described.Type: ApplicationFiled: February 9, 2010Publication date: February 2, 2012Applicants: XAVIER UNIVERSITY OF LOUISIANA, TULANE UNIVERSITYInventors: Barbara S. Beckman, Maryam Foroozesh, Jiawang Liu
-
Publication number: 20080268047Abstract: A process for making controlled release pharmaceutical formulations is provided, which comprises supplying a plurality of solutions with syringe pumps for fluid bed coating, coating a substrate with a pH dependent soluble polymer solution, coating the polymer coated substrate with at least one layer of a solution of a therapeutically active substance and at least one layer of a second polymer solution, and alternating the layers so that the number, order, and volume of the layers controls the release of the therapeutically active substance. In alternate embodiments, the consecutively applied layers may contain coating materials, active ingredients or a mixture of coating materials and active ingredients; the layers can be applied in varying order. Also provided is a system for applying the coatings, wherein the syringe pumps are controlled by a computer in accordance with predetermined instructions.Type: ApplicationFiled: April 24, 2007Publication date: October 30, 2008Applicant: Xavier University of LouisianaInventors: Tarun Kumar Mandal, Richard A. Graves, Dakshinamurthy Devanga Chinta
-
Publication number: 20080139534Abstract: Disclosed are bisbenzamidine and bisbenzamidoxime compounds useful for treatment of treatment of trypanosomiasis. The compounds disclosed are useful for treating mammals infected with parasitic hemoflagellates, in particular Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense.Type: ApplicationFiled: December 7, 2007Publication date: June 12, 2008Applicant: XAVIER UNIVERSITY OF LOUISIANAInventors: Tien L. HUANG, Jean Jacques VANDEN EYNDE, Annie MAYENCE, Cyrus BACCHI, Isaac O. DONKOR, Nageswara R. KODE